Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience

BACKGROUND: Vandetanib is the most widely used tyrosine kinase inhibitor for the treatment of patients with advanced medullary thyroid cancer (MTC). However, only limited data regarding its use outside clinical trials are available. We aimed to evaluate the efficacy and safety of vandetanib in patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Endocrinol Metab (Seoul)
Main Authors: Kim, Mijin, Yoon, Jee Hee, Ahn, Jonghwa, Jeon, Min Ji, Kim, Hee Kyung, Lim, Dong Jun, Kang, Ho-Cheol, Kim, In Joo, Shong, Young Kee, Kim, Tae Yong, Kim, Bo Hyun
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Endocrine Society 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7520595/
https://ncbi.nlm.nih.gov/pubmed/32981301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3803/EnM.2020.687
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados